Remon et al. have previously demonstrated the use of eTAm-Seq technology to aid in selection of targeted treatment in a prospective cohort of 48 EGFR-mutant advanced NSCLC patients with acquired resistance to EGFR TKIs, and without an available tissue biopsy [15]. Here, EGFR is linked to non-small cell lung carcinoma.